DANONE (BSN.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BSN - FR0000120644 - Common Stock
77.48 EUR
+0.26 (+0.34%)
Taking everything into account, BSN scores 5 out of 10 in our fundamental rating. BSN was compared to 59 industry peers in the Food Products industry. While BSN has a great profitability rating, there are some minor concerns on its financial health. BSN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BSN had positive earnings in the past year.
In the past year BSN had a positive cash flow from operations.
BSN had positive earnings in each of the past 5 years.
BSN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BSN has a better Return On Assets (4.20%) than 64.41% of its industry peers.
With a decent Return On Equity value of 11.59%, BSN is doing good in the industry, outperforming 64.41% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 6.83%, BSN is in the better half of the industry, outperforming 66.10% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BSN is in line with the industry average of 7.13%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
The Profit Margin of BSN (6.72%) is better than 74.58% of its industry peers.
BSN's Profit Margin has been stable in the last couple of years.
The Operating Margin of BSN (13.25%) is better than 79.66% of its industry peers.
In the last couple of years the Operating Margin of BSN has declined.
BSN has a better Gross Margin (50.47%) than 79.66% of its industry peers.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BSN is creating some value.
BSN has more shares outstanding than it did 1 year ago.
BSN has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BSN has been reduced compared to a year ago.
2.2 Solvency
BSN has an Altman-Z score of 2.55. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.55, BSN is in the better half of the industry, outperforming 62.71% of the companies in the same industry.
The Debt to FCF ratio of BSN is 5.07, which is a neutral value as it means it would take BSN, 5.07 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BSN (5.07) is better than 71.19% of its industry peers.
A Debt/Equity ratio of 0.83 indicates that BSN is somewhat dependend on debt financing.
The Debt to Equity ratio of BSN (0.83) is worse than 67.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.55 |
ROIC/WACC1.06
WACC6.46%
2.3 Liquidity
BSN has a Current Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
BSN's Current ratio of 0.95 is on the low side compared to the rest of the industry. BSN is outperformed by 74.58% of its industry peers.
BSN has a Quick Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.78, BSN is in line with its industry, outperforming 40.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.47%.
BSN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.17% yearly.
Looking at the last year, BSN shows a small growth in Revenue. The Revenue has grown by 0.54% in the last year.
BSN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.60% yearly.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
BSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.39% yearly.
Based on estimates for the next years, BSN will show a small growth in Revenue. The Revenue will grow by 3.15% on average per year.
EPS Next Y8%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
EPS Next 5Y6.39%
Revenue Next Year0.68%
Revenue Next 2Y1.86%
Revenue Next 3Y2.53%
Revenue Next 5Y3.15%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BSN is valuated rather expensively with a Price/Earnings ratio of 20.72.
Compared to the rest of the industry, the Price/Earnings ratio of BSN is on the same level as its industry peers.
When comparing the Price/Earnings ratio of BSN to the average of the S&P500 Index (26.15), we can say BSN is valued slightly cheaper.
BSN is valuated rather expensively with a Price/Forward Earnings ratio of 18.52.
BSN's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. BSN is more expensive than 61.02% of the companies in the same industry.
BSN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.12, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.72 | ||
| Fwd PE | 18.52 |
4.2 Price Multiples
BSN's Enterprise Value to EBITDA ratio is in line with the industry average.
BSN's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.4 | ||
| EV/EBITDA | 11.12 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.59
PEG (5Y)N/A
EPS Next 2Y7.34%
EPS Next 3Y7.61%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.79%. Purely for dividend investing, there may be better candidates out there.
BSN's Dividend Yield is comparable with the industry average which is at 3.35.
Compared to an average S&P500 Dividend Yield of 2.41, BSN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.79% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
74.99% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP74.99%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
FRA:BSN (11/26/2025, 7:00:00 PM)
77.48
+0.26 (+0.34%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners55.49%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap52.79B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts74.84
Price Target80.89 (4.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.79% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.83%
PT rev (3m)4.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.33%
EPS NY rev (3m)0.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.72 | ||
| Fwd PE | 18.52 | ||
| P/S | 1.93 | ||
| P/FCF | 18.4 | ||
| P/OCF | 13.73 | ||
| P/B | 3.33 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.12 |
EPS(TTM)3.74
EY4.83%
EPS(NY)4.18
Fwd EY5.4%
FCF(TTM)4.21
FCFY5.43%
OCF(TTM)5.64
OCFY7.28%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.59
PEG (5Y)N/A
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.55 |
F-Score8
WACC6.46%
ROIC/WACC1.06
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y8%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
EPS Next 5Y6.39%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.68%
Revenue Next 2Y1.86%
Revenue Next 3Y2.53%
Revenue Next 5Y3.15%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.38%
EBIT Next 3Y14.38%
EBIT Next 5Y10.92%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status of DANONE (BSN.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of DANONE (BSN.DE) stock?
The Price/Earnings (PE) ratio for DANONE (BSN.DE) is 20.72 and the Price/Book (PB) ratio is 3.33.
Can you provide the expected EPS growth for BSN stock?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 8% in the next year.